Zydus & CMS enter pact for Desidustat in Greater China

Pharma company Zydus has entered into a licensing pact with China Medical System Holdings Ltd (CMS) for the development and commercialisation of Desidustat, which is an innovative candidate, in Greater China.

Desidustat is a novel oral HIF-PH inhibitor used for the treatment of anemia in patients with Chronic Kidney Disease (CKD) not-on-dialysis and for the treatment of anemia CKD patients on dialysis in Greater China, Zydus said in a statement.

"Under the license agreement, CMS will pay Zydus an initial upfront payment, regulatory milestones, sales milestones and royalties on net sales of the product," it added.

However, no financial details about the agreement were given by Zydus and said, "The commercial terms of the license agreement are confidential."

Under the agreement, CMS will be responsible for development, registration and commercialisation of Desidustat in Greater China.

"The licensing agreement with CMS will facilitate the development and commercialisation of Desidustat in Greater China and make this innovative candidate available to millions of CKD patients living with anemia," said Zydus Group Chairman Mr Pankaj R Patel.

CKD is a serious medical condition which is an unmet healthcare need involving gradual loss of functioning of kidneys eventually leading to kidney failure, Zydus said.

Shares of Cadila Healthcare, the listed entity of the group, closed at Rs 267.25 (US$ 3.82) on BSE, down 0.69 per cent from the previous close.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.